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The pregnancy hormones human chorionic
gonadotropin and progesterone induce human
embryonic stem cell proliferation and
differentiation into neuroectodermal rosettes
Miguel J Gallego1†, Prashob Porayette1†, Maria M Kaltcheva1, Richard L Bowen2, Sivan Vadakkadath Meethal1,5,
Craig S Atwood1,3,4*
Abstract
Introduction: The physiological signals that direct the division and differentiation of the zygote to form a
blastocyst, and subsequent embryonic stem cell division and differentiation during early embryogenesis, are
unknown. Although a number of growth factors, including the pregnancy-associated hormone human chorionic
gonadotropin (hCG) are secreted by trophoblasts that lie adjacent to the embryoblast in the blastocyst, it is not
known whether these growth factors directly signal human embryonic stem cells (hESCs).
Methods: Here we used hESCs as a model of inner cell mass differentiation to examine the hormonal requirements
for the formation of embryoid bodies (EB’s; akin to blastulation) and neuroectodermal rosettes (akin to neurulation).
Results: We found that hCG promotes the division of hESCs and their differentiation into EB’s and
neuroectodermal rosettes. Inhibition of luteinizing hormone/chorionic gonadotropin receptor (LHCGR) signaling
suppresses hESC proliferation, an effect that is reversed by treatment with hCG. hCG treatment rapidly upregulates
steroidogenic acute regulatory protein (StAR)-mediated cholesterol transport and the synthesis of progesterone
(P4). hESCs express P4 receptor A, and treatment of hESC colonies with P4 induces neurulation, as demonstrated by
the expression of nestin and the formation of columnar neuroectodermal cells that organize into neural tubelike
rosettes. Suppression of P4 signaling by withdrawing P4 or treating with the P4-receptor antagonist RU-486 inhibits
the differentiation of hESC colonies into EB’s and rosettes.
Conclusions: Our findings indicate that hCG signaling via LHCGR on hESC promotes proliferation and
differentiation during blastulation and neurulation. These findings suggest that trophoblastic hCG secretion and
signaling to the adjacent embryoblast could be the commencement of trophic support by placental tissues in the
growth and development of the human embryo.
Introduction
Zygotic division into a blastocyst establishes the extra-
embryonic tissues (trophoblast layer or outer cell mass)
that support the embryonic embryoblast (inner cell
mass) early in embryogenesis. Trophoblasts secrete an
array of hormones [1-4], including hCG, during the
migration of the blastocyst through the fallopian tube
and its implantation into the endometrium. The dra-
matic elevation in the production of hCG by tropho-
blasts at this early embryonic stage (from 5 to ≥1,000
mIU/ml in the maternal serum) [2,5] signals both the
corpus luteum and trophoblast [3] to synthesize and
secrete P4 [6]. This is required for the maintenance of
the endometrium, blastocyst attachment, and syncytio-
trophoblast invasion into the endometrium [7].
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However, the role of hCG in early human embryogen-
esis is unknown.
Given the close spatial localization of the developing
trophoblast layer to the embryoblast, it is conceivable
that trophoblast-associated hormones directly signal the
growth and development of the embryoblast. hCG, and
luteinizing hormone (LH), which shares 83% amino acid
sequence homology, bind a common receptor, the LH/
human chorionic gonadotropin receptor (LHCGR) with
similar affinity [8]. LHCGR has been identified on all
tissues studied to date (reviewed in [9,10]), although it
has not been reported on hESCs.
Recent evidence from our laboratory supports tropho-
blastic hCG and P4 signaling to embryoblast-derived
hESCs and includes (a) hCG markedly increases hESC
expression of the adhesion and neuritogenic protein
amyloid-b precursor protein (AbPP) [11], (b) P4 is
required for nonamyloidogenic processing of AbPP dur-
ing hESC differentiation [11], and (c) P4 signaling is
necessary for human embryoid body (EB) differentiation
[4]. Moreover, it is known that (hyperglycosylated)
hCGb has potent cell growth and invasion properties
and acts as an autocrine factor on extravillous invasive
cytotrophoblast cells to initiate and control invasion
during implantation and the establishment of hemo-
chorial placentation [12]. hCG also promotes these pro-
cesses during malignancy in invasive hydatidiform mole,
choriocarcinoma, and testicular cancers [12].
In this study we tested whether the trophoblastic hor-
mones hCG and P4 signal hESC proliferation and differ-
entiation. By using this in vitro model of early human
embryogenesis, we found that hCG/LH signal via
LHCGR to promote hESC proliferation and steroidogen-
esis (P4 synthesis), and that P4 signaling is obligatory for
both EB and neuroectodermal rosette differentiation.
Materials and methods
Human embryonic stem cell culture
Propagation of human embryonic stem cells
Pluripotent H9 hESCs (passage 22 to 32; XX karyotype;
also known as WA09, a National Institutes of Health
registered line) were obtained from the WiCell Research
Institute (Madison, WI). The research was approved by
the UW-Madison Department of Medicine. Cells were
plated onto irradiated mouse embryonic fibroblast
(MEF) cells (1.875 × 105 cells per well; Biovintage, San
Diego, CA) in six-well plates (Fisher Scientific, Pitts-
burgh, PA) coated with 1 ml of sterile 0.1% gelatin
(Sigma-Aldrich Co., St. Louis, MO) solution. Before the
addition of hESCs, MEF cells were grown in Dulbecco’s
Modified Eagle Media (DMEM) (Invitrogen, Carlsbad,
CA) supplemented with 10% heat-inactivated fetal
bovine serum (FBS; Invitrogen) and 1% nonessential
amino acids (NEAAs; Invitrogen). After 24 hours of
MEF plating, hESCs were plated on this MEF feeder
layer and grown in the presence of DMEM-F12 media
(Invitrogen) supplemented with 1% NEAA, 1 mM
L-glutamine (Invitrogen), 0.1 mM 2-mercaptoethanol
(Sigma-Aldrich Co.), 4 ng/ml bFGF (Invitrogen), and
20% Knockout Serum Replacement (KOSR; Invitrogen).
Continual propagation of cells required colonies to be
enzymatically lifted with 1 ml of a sterile solution of col-
lagenase type IV (Invitrogen) (1 mg/ml of DMEM-F12),
dissected into multiple small pieces, and transferred
onto a fresh MEF feeder layer every 4 to 5 days. hESCs
also were grown on Matrigel (BD Biosciences, San Jose,
CA), a basement-membrane preparation extracted from
a murine Englebreth-Holm-Swarm sarcoma, in the pre-
sence of mTeSR1 medium (StemCell Technologies, Inc.,
Vancouver, British Columbia, Canada), a defined culture
medium developed by WiCell Research Institute [13].
Matrigel (100 μg/ml in DMEM-F12; 1 ml) was added to
each well of a six-well plate and left for 1 hour at room
temperature or at 4°C overnight. hESCs were transferred
onto these plates, and cells were passaged by enzymatic
lifting with a sterile solution of neutral protease
(Dispase; 1 mg/ml in DMEM-F12; Invitrogen), the colo-
nies dissected into multiple small pieces and transferred
onto new plates coated with Matrigel, and cultured in
mTeSR1 medium. The culture medium (2.5 ml per well)
was replaced every day in all these culture conditions.
Differentiation of hESCs into embryoid bodies
This protocol mimics the formation of the blastocyst
during human embryogenesis [14]. Pluripotent hESCs
(H9) grown on MEF in a six-well plate were rinsed
twice with 1 ml of Dulbecco’s Phosphate-Buffered Saline
(DPBS, without calcium or magnesium; Invitrogen) per
well. Colonies were then incubated with 1 ml of Dispase
(0.5 mg/ml in DMEM-F12) at 37°C, 5% CO2, until the
colonies detached intact while avoiding dispersing the
colonies into single cells. T25 flasks (Fisher Scientific)
were incubated with 5 ml of a 2% poly (2-hydroxyethyl
methacrylate) (Poly-HEMA; Sigma-Aldrich Co.) solution
for 5 minutes. The flask was placed in a horizontal posi-
tion for 5 minutes with the cap on. This allowed opti-
mal coating of the working-surface area of the flask.
This process was repeated for each side of the flask. The
caps of coated flasks were opened, and the Poly-HEMA
solution was sucked off. The open flasks were allowed
to remain in the hood for 1 hour to dry. After 1 hour,
the surface was washed twice with DPBS, and the
detached hESC colonies were cultured in 15% Charac-
terized FBS (Invitrogen) and 85% Iscove’s Modified
Dulbecco’s Medium (IMDM; Invitrogen) in these Poly-
HEMA-coated T25 flasks and incubated under standard
conditions (37°C, 5% CO2) on an orbital shaker (Boekel
Orbitron, Feasterville, PA) with constant gentle rocking
for 10 to 14 days to allow the hESCs to aggregate into
Gallego et al. Stem Cell Research & Therapy 2010, 1:28
http://stemcellres.com/content/1/4/28
Page 2 of 13
cystic spheroidal structures. The Poly-HEMA coat and
the constant gentle rocking prevented the adherence of
these spheroidal structures to the flask.
Differentiation of hESCs into neural precursor cells
The protocol described later for the differentiation of
hESCs into columnar neural precursor cells (NPCs)
mimics in vivo NPC development in terms of timing and
morphology [15]. In vitro, hESCs differentiate into
columnar NPCs that organize into neural tube-like
rosettes within 12 to 14 days. Considering that hESCs are
equivalent to a 5 to 6 day embryo, development of the
NPCs in vitro takes about 18 to 20 days, the time window
when the neural tube forms in a human embryo [16,17].
Pluripotent hESC (H9) colonies grown on MEF in six-
well plates were rinsed twice with DPBS (1 ml per well)
and then treated with Dispase (1 ml of 1 mg/ml in
DMEM-F12) and incubated at 37°C, 5% CO2 until the
edges of the colonies began to curl up. The plate was
then swirled to detach the colonies intact but without
dispersing the colonies into individual cells. The hESC
colonies were grown in T25 flasks in a special ES cell-
growth medium (78.5% DMEM-F12, 20% KOSR, 1%
NEAA, 1 mM L-glutamine, 0.1 mM 2-mercaptoethanol)
for 4 days with daily replacement of media to form ESC
aggregates. ESC aggregates were then adhered to the
culture surface, where they formed monolayer colonies
in a chemically defined neural induction medium (32.6%
F-12 (Invitrogen), 65.2% DMEM, 1% N2 supplement
(Invitrogen), 1% NEAA, 0.2% of 1 mg/ml Heparin
(Sigma-Aldrich Co.), and 10 ng/ml bFGF). Under this
culture condition, columnar NPCs appear in the center
of each colony and organize into neural tube-like
rosettes after a total of 9 to 10 days of differentiation
culture. The neural induction medium was replaced
every other day. The NPCs in the rosettes were selec-
tively isolated through differential enzymatic treatment
by using Dispase (0.5 mg/ml in DMEM-F12) and incu-
bated for 2 hours in neural induction medium to allow
the nonneural cells to attach differentially attach to the
T25 flasks. After this, the floating cells (mostly aggre-
gates of NPCs) were transferred to new T25 flasks
where they rolled up to form round clusters. Some of
these clusters were collected and probed for nestin to
confirm NPC differentiation. The remaining formed
clusters were continuously passaged by manually split-
ting the clusters by using a sterile scalpel.
Treatment of hESCs
Pluripotent H9 hESCs were plated in six-well plates
coated with Matrigel in 2.5 ml of mTeSR1 medium per
well. After overnight culture, cells were treated every
day in different experiments with (a) hCG (0 to 50,000
mIU/ml; Ray Biotech Inc., Norcross, GA) in mTeSR1
medium for 6 days; (b) LH (0 to 100 mIU/ml; National
Peptide Hormone Program, Harbor-UCLA, Los Angeles,
CA); (c) P4 (2 μM), E2 (10 nM), RU-486 (20 μM; stock
RU-486 was solubilized in EtOH and then diluted into
media; Sigma Laboratories, St. Louis, MO), DMSO
(equivalent volume to that added to sex steroids) and
EtOH (equivalent volume to that added to RU-486) for
5 to 10 days in TESR1 medium (lacking Li); (d) affinity
purified anti-LHCGR rabbit polyclonal antibody
(1:1,000, 1:200, 1:100 dilution) in combination with
hCG; or (e) lipofectamine (control), lipofectamine +
LHCGR sense oligonucleotides or lipofectamine +
LHCGR P-antisense oligonucleotides for 6 days. For
experiments using oligomers with phosphorothioate
bonds (antisense-P; Integrated DNA Technology, Coral-
ville, IA), oligomers were added to media (240 μl) that
had been preincubated with lipofectamine (4 ng/μl; Invi-
trogen) for 5 minutes at room temperature. This mix-
ture was then incubated at room temperature for
20 minutes before the addition to cells. Antisense-P was
used at a final concentration of 0.4 μM.
Cells were counted by using the trypan blue staining
method and collected in Dulbecco’s phosphate-buffered
saline (DPBS) and stored at -80°C before analysis of
mRNA or protein expression or both. Media from hCG-
treated cells were pooled each day for 6 days (15 ml
total), lyophilized, and resuspended in 2 ml of TESR1
medium for EIA of P4 (Cayman Chemical Company,
Ann Arbor, MI).
Progesterone receptor antagonist treatment of
hESC colonies
EB formation
ESCs were allowed to form colonies by culturing for
4 days on an MEF feeder layer, as described earlier, and
then were enzymatically lifted and the colonies placed
into EB medium (containing serum) in the absence
(control) or presence of RU-486 (20 μM) and rocked
gently for an additional 10 days to allow EB formation.
Structures were then assessed morphologically.
Rosette formation
hESCs were allowed to form colonies by culturing for
4 days on an MEF feeder layer. Colonies were then
enzymatically lifted and placed into EB medium (con-
taining serum) and rocked gently for an additional
4 days. Colonies were then placed in neural induction
media without P4 (using an especially made medium
containing all ingredients except P4), with P4 (2 μM),
and/or RU-486 (20 μM) for an additional 11 days. At
19 days, the structures were assessed morphologically
and then collected for immunoblot analyses.
mRNA Expression
Total RNA was isolated from cultured hES cells by
using the RNeasy Mini Kit (Qiagen, Valencia CA)
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according to the manufacturer’s instructions. LHCGR,
LHb, hCG, and steroid acute regulatory protein (StAR)
cDNA were synthesized and amplified by using the
SuperScript III One-Step RT-PCR system (Invitrogen).
Both cDNA synthesis and PCR amplification were car-
ried out by using gene-specific primers (Integrated-
DNA-Technologies, Coralville, IA): LHCGR forward 5′
CCCTCACCGTCATCACTCTAG 3′, reverse 5′ CGATT
TCACCTGCATGGC 3′, LHb forward 5′ GCTACTGC
CCCACCATGATG 3′, reverse 5′ ATGGACTCGAAG
CGCACATC 3′, Isoform V of hCGb forward 5′ ATCA
CCGTCAACACCACCATCTGT 3′, reverse 5′ AAGCCT
TTATTGTGGGAGGATCGG, StARD1 forward 5′ CGG
CAGCGACCCCACCACT 3′, reverse 5′AGCCGGAA-
CACCTTGCCCACAT 3′. PCR amplification of LHCGR
was performed for 35 cycles of 95°C for 30 seconds,
62°C for 45 seconds, 72°C for 60 seconds, and final
extension time of 5 minutes. PCR amplification of StAR
was performed for 35 cycles of 95°C for 30 seconds,
64°C for 45 seconds, 72°C for 60 seconds, and a final
extension time of 5 minutes. PCR amplification of LHb
was performed for 35 cycles of 95°C for 30 seconds, 63°
C for 45 seconds, 72°C for 60 seconds, and final exten-
sion time of 5 minutes. PCR amplification of hCG was
performed for 35 cycles of 95°C for 30 seconds, 63°C for
45 seconds, 72°C for 60 seconds, and final extension
time of 5 minutes. The PCR product was stained with
Gel Star Nucleic Acid Stain (Cambrex Bio Science,
Rockland, ME), run on 2.5% Metaphor agarose gel
(Cambrex Bio Science), and imaged by using EC3 Ima-
ging System (UVP Bioimaging System, Upland, CA).
Immunoblotting
Cells were collected and immunoblot analyses per-
formed as previously described [11,18]. Because of the
dramatic changes that occur in protein expression dur-
ing the dynamic developmental period under considera-
tion, it was difficult to find an internal control to
demonstrate equal protein loading (see [11,18]). Given
this variability, we chose to load samples according to
total protein, as previously described [19]. The following
antibodies were used throughout this study: Anti-human
nestin monoclonal antibody (Chemicon International,
Temecula, CA); affinity purified anti-human LH/hCG
receptor polyclonal antibody generated against the
N-terminal 15-38 amino acids (New England Peptides,
Atlanta, GA); anti-human Oct3/4 monoclonal antibody,
anti-human PR rabbit polyclonal antibody (C-19) gener-
ated against the C-terminus, glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) goat polyclonal antibody
(V-18), anti-human b-actin goat polyclonal antibody
(C-11), horseradish peroxidase-linked goat anti-mouse,
goat anti-rabbit, and donkey anti-goat IgG (Santa Cruz
Biotechnology); anti-human LHb polyclonal antibody
(National Hormone and Peptide Program, Harbor-
UCLA Medical Center, Torrance, CA) [20]; anti-human
StAR polyclonal antibody (a kind gift of Dr. Strauss,
University of Pennsylvania [21]).
Enzyme immunoassay
hESCs were treated with hCG (500 mIU/ml) in TESR1
media each day for 6 days, the media collected and
pooled each day (15 ml total), lyophilized and resus-
pended in 2 ml of TESR1 media for enzyme immunoas-
say (EIA) of P4 (Cayman Chemical Company) according
to the manufacturer’s instructions.
Statistical analysis
Statistical analysis was performed by using the Student’s
t test and ANOVA analyses followed by pair-wise com-
parisons with Fisher’s protected least significant differ-
ence procedure (PLSD) to determine significant changes
between treatment groups (Statview 5.0 & SuperAnova
3.0 programs; SAS Institute, Inc.).
Results
To examine the functionality of trophoblastic hCG
signaling to the embryoblast, we first examined whether
the LHCGR was expressed by pluripotent hESCs. Full-
length mature LHCGR (92 kDa) [2] was detected in
hESCs, and expression was not altered on differentiation
into EB’s, which recapitulate the early stages of peri-
mplantation embryos [22], or into neuroectodermal
rosettes, which consist of >90% columnar NPCs and are
the in vitro equivalent of a rudimentary neural tube [15]
(Figure 1a, upper panel). Decreased Oct-3/4 expression
(Figure 1a, middle panel) together with bright-field ana-
lysis (not shown) indicated lineage commitment and
loss of pluripotency during the differentiation of hESC
colonies into rosettes. RT-PCR of RNA extracted from
pluripotent hESCs confirmed the presence of LHCGR
message (Supplemental figure S1 in Additional file 1).
The comparable level of LHCGR expression between
the different cell lineages is suggestive of a basal
requirement for LH/hCG signaling during these early
stages of embryogenesis.
Because hCG is mitogenic toward epithelial and
endothelial cells of the endometrium and is a marker of
carcinogenesis [23], we tested whether hCG was gener-
ated by hESCs and is mitogenic toward hESCs. RT-PCR
amplification of RNA extracted from pluripotent hESCs
by using sequence-specific primers confirmed the pre-
sence of both hCGb isoform V and LHb message (data
not shown). Although full-length mature 30-kDa LH
protein (a-GSU + LHb subunits) and other variants of
LH (47 kDa and 60 kDa) [20] could be detected with
immunoblot analysis (Figure 1b), hCG was not detect-
able by immunoblot, as previously reported for hESCs
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[3], suggesting differential translational control of the
expression of these gonadotropins early in embryogen-
esis. These results suggest that before hESC differentia-
tion into trophoblasts, which are known to secrete hCG
[3], LH expressed by hESCs may act in an autocrine
manner on hESCs. To examine the requirement for LH/
hCG signaling in the proliferation of hESCs in vitro, we
treated hESCs with P-antisense oligonucleotides against
LHCGR. P-antisense oligonucleotides significantly
decreased hESC proliferation (48%) compared with
sense oligonucleotide-treated hESCs (Figure 1c). To
confirm that hESC production of LH or trophoblastic
production of hCG promotes hESC proliferation, we
treated hESCs with increasing concentrations of an anti-
body against amino acids 15 to 38 of the extracellular
activation site of LHCGR (Figure 1d) [24]. This antibody
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Figure 1 hCG signals hESC proliferation via LHCGR. (a) Pluripotent H9 hESC, EBs and NPC lysates were analyzed by immunoblot with (i) an
affinity-purified anti-human LH/hCG receptor polyclonal antibody against the N-terminal 15-38 amino acids; (ii) a monoclonal antibody against
Oct-3/4 (C-10; against 1-134 amino acids of human Oct-4), and (iii) monoclonal antibodies against human b-actin and GAPDH [11,18]. Molecular-
weight markers are shown on the left of immunoblots. (b) Protein from cell lysates of hESCs were analyzed with immunoblot by using a
polyclonal antibody against LHb [20]. (c) hESCs were treated with lipofectamine (control), lipofectamine + LHCGR sense oligonucleotides, or
lipofectamine + LHCGR antisense-P oligonucleotides for 6 days, and the cells were then counted by using the trypan blue method. Results are
expressed as mean ± SEM, n = 4; significant differences between groups is indicated by different letters, P < 0.05. (d) Schematic of the LHCGR
activation site and binding site of rabbit polyclonal antibody against amino acids 15 to 38 of the extracellular binding domain of LHCGR. (e)
hESCs grown in six-well plates coated with Matrigel in mTeSR1 media were treated for 6 days with (i) hCG (500 mIU/ml; lane A); (ii) increasing
concentrations of the affinity-purified rabbit polyclonal antibody against amino acids 15 to 38 of the extracellular binding domain of LH/hCG
receptor (1:1,000, 1:200, 1:100; lanes B, C, and D, respectively); and (iii) in combination with (500 mIU/ml of hCG (lanes E, F, and G). Cell number
was counted by using the trypan blue assay. Results are expressed as mean ± SEM, n = 3; *P < 0.05; **P < 0.005 compared with day 6 control.
(f) hESCs were cultured in growth factor-free TESR1 medium ± hCG (500 mIU/ml) for 6 days, and cell number was measured by using the
trypan blue assay. Results are expressed as mean ± SEM, n = 3; **P < 0.005 compared with 6 day control.
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significantly reduced hESC proliferation in a dose-
dependent fashion compared with 6-day untreated
controls (Figure 1e; 48% reduction with 1:100 diluted
antibody). Addition of hCG to hESCs treated with this
blocking antibody reversed this effect, confirming the
specificity of the antibody for the receptor and of hCG
signaling for hESC proliferation. Similar results were
obtained with LH treatment (data not shown). Treat-
ment of hESC with a physiologically relevant concentra-
tion of hCG (500 mIU/ml) in growth factor-free TESR1
culture medium resulted in a 3.3-fold increase in cell
proliferation after 6 days (Figure 1f). Surprisingly, a
similar increase (3.7-fold) in hESC proliferation was
observed in growth factor-free TESR1 culture media
(that is, TESR1 media containing no bFGF and TGF-b),
suggesting the autocrine production of hCG/LH
(or other mitogenic factors) by hESCs or hESCs that
had differentiated into trophoblasts in our cultures, as
previously reported by Thomson et al. [25]. The high
binding affinities (Kd ≈0.4-5.5 × 10
-10 M) of hCG/LH for
the human receptor [26,27] indicates that the autocrine
production of even very low concentrations of these
gonadotropins by hESCs (or trophoblasts, as reported by
Golos et al., [3]) is sufficient to signal hESC prolifera-
tion. A low level of hCG/LH expression by hESC/tro-
phoblasts also is consistent with the high binding
capacity (~2.2 fmol/mg tissue) of hCG for LHCGR [26].
In this respect, knockdown of Oct4 expression in hESC
induces hCG and Gcm1 expression [28] and indicates
that any small differentiation of hESC in our cultures
may provide sufficient hCG for hESC proliferation.
Together, these results suggest the presence of an hCG/
LH-dependent mechanism that signals embryonic
growth.
hCG functions to increase trophoblast and corpus
luteal P4 production [6,29]. To examine whether hCG
induces steroidogenesis in hESCs, as in steroidogenic tis-
sues, we examined the expression of StAR, a key rate-
limiting step in the production of steroids [30]. hESCs
were found to express StAR mRNA and protein (37-kDa,
30-kDa, and 20-kDa variants; Figure 2a). Increases were
found in the expression of the mature variant (37 kDa)
and decreases in the expression of the truncated (30- and
20-kDa) variants of StAR with differentiation of hESCs
into EBs and rosettes (Figure 2a). Because truncation of
the 37-kDa to the 30/32-kDa variants of StAR is indica-
tive of increased cholesterol transport across the mito-
chondrial membrane for steroidogenesis [30], these
results suggest a decreased requirement for steroidogen-
esis in more-differentiated cell lineages.
To assess the steroidogenic potential of hESCs, we
treated hESCs with hCG and measured P4 secretion into
the media. hCG (500 mIU/ml) treatment increased P4
secretion into the media 15-fold (Figure 2b), suggesting
that P4 may signal hESCs.
Analysis of hESCs and EBs indicated that these cells
express P4 receptor A (PR-A) (Figure 3a), as was pre-
viously reported for the mRNA [31] and murine ESCs
[32], suggesting that P4 could signal hESC differentia-
tion. PR-A expression did not change in hESCs after
treatment with P4 or the PR antagonist RU-486 (Figure
3a). That PR-A is functional in hESCs is supported by
the finding that P4 treatment decreases truncation of the
37-kDa StAR variant (increasing the 37- to 30-kDa ratio
by 83%; Figure 3b). These results also indicate that
mechanisms at the level of both StAR expression and
processing exist to regulate hESC steroidogenesis.
Together, these results indicate that negative-feedback
pathways exist for the regulation of hCG/LH signaling
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Figure 2 hCG induces the synthesis and secretion of P4 by
hESCs. (a) Total RNA isolated from hESCs was amplified by RT-PCR
by using two pairs of sequence-specific primers for StAR. The
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and cholesterol uptake for the synthesis of sex steroids
in hESCs and differentiating lineages.
Increasing concentrations of hCG suppress the pluri-
potent marker Oct-3/4 (Supplemental figure S2 in Addi-
tional file 1), suggesting that hCG, or steroid production
initiated by hCG signaling, can direct lineage commit-
ment. To test the effects of sex steroids on hESC
proliferation and differentiation, we treated hESCs with
E2, P4, and E2 + P4 and observed a significant decrease
in cell proliferation by 29%, 16%, and 23%, respectively,
compared with untreated control (Figure 4a). These
results were consistent with the slight decrease in cell
proliferation observed after hCG treatment (Figure 1f)
that induced significant P4 secretion (Figure 2b).
A screen of germ-layer markers indicated that P4, and,
to a lesser extent, E2, increase the expression of nestin,
an early marker of NPC formation, in hESCs (Figure
4b). Interestingly, E2 ’priming’ has been shown to be
required for induction of PR expression in other tissues
[33]. Thus, the increase in nestin expression with E2
treatment may reflect increased PR expression together
with endogenous P4 signaling, and explain the current
requirement for serum priming of hESC colonies in the
preparation of neuroectodermal rosettes. Previous stu-
dies have demonstrated the importance of P4 and
related steroids as neurotrophic agents that promote
adult neurogenesis, neuronal survival, and neuroprotec-
tion [34-36].
The induction of nestin expression by P4 reveals a
pivotal function for this pregnancy hormone during
ectoderm formation. To confirm the requirement for P4
signaling in embryoblast development, hESC colonies
just before entering the EB stage were treated with or
without the PR antagonist RU-486 [37]. When com-
pared with controls, colonies treated with RU-486 failed
to form cystic structures (cavitation) and instead formed
solid irregular spheres (Figure 4c) that did not express
nestin (see Supplemental figure S3 in Additional file 1).
We next examined the requirement for P4 signaling
during neurulation. hESC colonies grown into a pre-EB
stage were treated with either P4, RU-486, P4 + RU-486,
or neither by using an especially made medium contain-
ing all ingredients except P4. In the presence of P4, con-
trol rosettes displayed a minimum of three rosette
structures inside of the cavity (Figure 4c(iii)). Compared
with controls, pre-EBs treated without P4 (Figure 4c(v))or
with RU-486 (Figure 4c(iv)) retained a spherical shape
but failed to form rosettes with columnar neuroectoder-
mal cells after 17 days in culture. Morphologic changes
were more severe in the absence of P4 than with RU-486.
That neuroectoderm failed to form was confirmed by the
absence of nestin expression in RU-486-treated com-
pared with P4-treated pre-EBs (Figure 4d). These results
confirm our previously reported findings that P4 is the
differentiation factor present in the neural induction
media (N2 component) essential for neuroectodermal
rosettes formation [4]. These results therefore suggest an
obligatory role for P4 signaling in gastrulation and neuru-
lation during early embryogenesis.
hCG/LH signaling via the LHCGR increases hESC
proliferation, but also P4 synthesis that decreases cell
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polyclonal antibody (C-19) generated against the C-terminus, b-actin
antibody and GAPDH antibody [11,18]. EBs were treated ± RU-486
(20 μM) and analyzed for these proteins. (b) hESCs were treated
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proliferation and promotes differentiation. At what point
these functions bifurcate, and what other factors regu-
late hCG-induced proliferation versus hCG-induced P4-
mediated differentiation (for example, BMP signaling)
remain to be determined. Interestingly, hESCs default
toward a primitive neural stem cell fate if maintained
for any length of time in culture [38]. Because hESCs
express gonadotropins (Figure 1b), and hCG signaling
promotes P4 production (Figure 2b), which induces line-
age commitment toward a neuroectodermal phenotype
(Figures 4b, c), we tested whether hCG might act to dif-
ferentiate hESCs toward a neuronal lineage. hCG treat-
ment induced nestin expression (205-kDa variant) in
hESCs (Figure 4e), indicating that endogenous gonado-
tropin production by hESCs (Figure 1) or trophoblastic
cells [3] may be sufficient for NPC formation, thereby
explaining the extrinsic hormonal signals regulating the
‘default pathway’ of hESC differentiation into neuronal
lineages [38].
Discussion
These results indicate that trophoblastic hCG production
adjacent to the embryoblast is required not only for tro-
phoblast steroidogenesis and attachment to the uterine
wall, but also for signaling normal growth and develop-
ment of the embryoblast. hCG has known growth and
Figure 4 P4 promotes blastulation and neurulation. (a) hESCs were grown in lithium-free TESR1 medium in the presence of E2 (10 nM) or P4
(2 μM) or E2 (10 nM) + P4 (2 μM) for 6 days, and cell numbers were measured by using the trypan blue assay. Results are expressed as mean ±
SEM, n = 4; *P < 0.05; **P < 0.005 compared with 6 day control. (b) Equal amounts of protein from cell lysates of hESCs treated for 9 days as
described earlier were analyzed with immunoblot by using a monoclonal antibody against nestin (clone 10C2). (c) EB formation: hESCs were
allowed to form colonies by culturing for 4 days on an MEF feeder layer, as described earlier, and then were enzymatically lifted, and the colonies
were placed into EB medium (containing serum) in the absence (i; control) or presence (ii) of RU-486 (20 μM) and rocked gently for an additional
10 days to allow EB formation. Structures were then assessed morphologically. Rosette formation: hESCs were allowed to form colonies by culturing
for 4 days on an MEF feeder layer; colonies were then enzymatically lifted and placed into EB medium (containing serum) and rocked gently for an
additional 4 days. Colonies were then placed in neural induction medium with P4 (2 μM) (iii), without P4 (v) or with P4 (2 μM) + RU-486 (20 μM) (iv)
for an additional 11 days. At 19 days, the structures were analyzed morphologically. (d) The structures in (c) were collected, and equal amounts of
protein from cell lysates were analyzed for nestin with immunoblot analysis. (e) hESCs were grown in mTeSR1 medium and treated with 500 mIU/
ml hCG for 8 days. Cells were collected, protein content determined by using the BCA assay, equal amounts of protein were run on SDS-PAGE, and
the immunoblot was probed for human nestin. Molecular-weight markers are shown on the left of immunoblots.
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differentiation functions during pregnancy, in which
extravillous invasive cytotrophoblast cells [39,40] or non-
villous cytotrophoblast cells [41,42] secrete hyperglycosy-
lated hCG that acts in an autocrine/paracrine manner to
promote invasion [40,43]. Hyperglycosylated hCG-
induced invasion of extravillous cytotrophoblast cells is
critical for successful pregnancy implantation [44].
Hyperglycosylated hCG also promotes growth and inva-
sion of choriocarcinoma cells across membranes in vitro
and promotes extensive invasion, growth, and malig-
nancy of choriocarcinoma cells transplanted into nude
mice in vivo [39,40]. Regular hCG also has growth prop-
erties, promoting the induction of neoangiogenesis dur-
ing endometrial vascularization [45,46]. Moreover, the
free glycoprotein a-subunit of gonadotropins has been
shown to stimulate differentiation of prolactin cells in the
pituitary [47] and endometrial stromal cell decidualiza-
tion in the placenta [48]. As recently commented on,
these well-described growth and malignancy properties
of hCG have been largely neglected [49,50]. In our
experiments, blocking LHCGR signaling with antisense
and a specific blocking antibody suppressed hESC growth
(Figure 2) strongly supports a role of hCG in promoting
embryoblast growth. Although regular hCG did not
increase cell proliferation above that of media containing
no growth factors (Figure 1f), it is likely that either regu-
lar or glycosylated forms of hCG are the mitogenic factor
promoting hESC division.
Although the structural importance of P4 and allopro-
gesterone has previously been recognized by its early
synthesis (by at least day 13) within the developing rat
central nervous system [51], our results demonstrate an
earlier (within the first 7 days) and absolute requirement
for P4 during both EB and neuroectodermal rosette differ-
entiation, as indicated by the findings that (a) PR-A is
expressed by hESCs and EBs, (b) RU-486 prevents normal
cavitation of hESC colonies and columnar neuroectoder-
mal rosette formation, (c) RU-486 prevents nestin expres-
sion, (d) P4 induces nestin expression in hESC, (e) P4
withdrawal from pre-EBs inhibits neuroectodermal rosette
formation, and (f) hCG upregulates StAR processing for
cholesterol transport and P4 synthesis and secretion.
Extrapolation of these results from this model system
would suggest that paracrine/juxtacrine signaling of hCG
for mobilization of cholesterol for P4 production by the
embryoblast/syncytiotrophoblast after conception is essen-
tial for blastulation and neurulation. The P4-induced dif-
ferentiation of hESCs into neuroectodermal cells may be
mediated by the alternate processing of the AbPP, because
AbPP processing toward the nonamyloidogenic pathway
after the addition of P4 (neural induction media) is
required for neural precursor cell formation [18].
Progestogens are demonstrated neurotrophic agents that
promote adult neurogenesis, neuronal survival, and
neuroprotection [34,35,52-58]. P4 is necessary and suffi-
cient (in neurobasal media) for the maintenance and
differentiation of primary hippocampal/cortical/striatal
neurons in vitro [34]. That P4 is the hormone regulating
these key early developmental events is consistent with its
location high in the steroid synthetic pathway; P4 is the
first steroid synthesized from pregnenolone, the precursor
to all other steroids. Moreover, the expression of PR-A by
hESCs and EBs, and the findings that PR-A expression is
not altered by either agonists or antagonists suggests an
important function for PR-A signaling early in embryogen-
esis. The potential for P4 to regulate organogenesis has
been reported during puberty and adulthood, in which P4
is obligatory for the development of the tertiary ducts on
the mammary gland, and the physiological differentiation
of the lobuloalveolar system from the lobular buds [59]. In
the adult, P4 also has been demonstrated to regulate bone
formation [60], promote angiogenesis and arteriogenesis
[61], and promote formation of the placenta.
Support for LH in mediating neurogenesis has been
reported in mice, in which LH induces neurogenesis in
the adult hippocampus [62]. Whether these properties
of LH/hCG in the adult brain are mediated via P4, as we
demonstrated for hESCs (Figures 1 through 4) remains
to be determined, although progestogens have been
shown to increase significantly rat neuroprogenitor cell
and human neural stem cell proliferation [35,63], and to
promote neurite development and migration that lead to
changes in synaptogenesis [64-67]. The autocrine/para-
crine signaling of hCG for P4 synthesis within the blas-
tocyst is consistent with the recent findings that a ‘mini-
HPG’ axis appears within the extrahypothalamic/pitui-
tary brain that serves to regulate brain neurosteroid pro-
duction [68]. Identification of other members (hormones
and hormone receptors) of the HPG axis that regulate
hCG/LH production, for example, might be predicted.
The requirement for P4 during cavitation processes
indicates the structural influence of these molecular
pathways on the developing embryo within the first
7 days, but also on the formation of the neural tube at
around day 17 to 19, which will influence future neural
connectivity. The suppression of P4 signaling at this
time (for example, with RU-486) [69] will block these
time-sensitive developmental processes. Given that the
relative binding affinity of RU-486 for the PR is twice
that of P4 [70], and that treatment of hESC with 20 μM
RU-486 in our study (Figures 3 and 4) is equivalent to
the dosage used for the termination of pregnancies (~6-
19 μM) [37], administration of RU-486 would clearly
have a negative effect on the developing embryo. Thus,
the abortifacient effects of RU-486 in blocking PR sig-
naling therefore also extend to blocking blastulation and
neurulation and the normal growth and development of
the embryo.
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Figure 5 Model of the spatiotemporal autocrine and paracrine pathways regulating blastulation and neurulation. Based on our current
knowledge and the data presented in this article regarding the hormonal regulation of early embryogenesis, we present a model of (a) the
time course for the induction of embryoid bodies and neuroectodermal rosettes by hCG and P4, and (b) putative autocrine and endocrine
signaling pathways involved in cell proliferation, steroidogenesis, and differentiation of the blastocyst and primitive neural tube.
Gallego et al. Stem Cell Research & Therapy 2010, 1:28
http://stemcellres.com/content/1/4/28
Page 10 of 13
The maintenance of hESCs in a pluripotent state in
culture is dependent on the presence of a member of the
FGF family as well as a member of the TGF-b superfam-
ily [25]. Whether FGF and TGF-b also are physiologic
signals produced by trophoblastic cells that signal the
embryoblast is unknown, although FGF and activins have
known growth and differentiation properties [13,71].
We present a model of the time course for in vitro
differentiation of hESCs into an EB and into a neuroec-
todermal rosette with the physiological hormones hCG
and P4 (Figure 5a), and of the autocrine and paracrine
pathways within the blastocyst that might operate to
regulate blastocyst and neuroectodermal development
(Figure 5b). Our data suggest that trophoblastic hCG
production adjacent to the embryoblast could be
required, not only for trophoblast steroidogenesis and
attachment of the blastocyst to the uterine wall [72], but
also for signaling normal proliferation and differentia-
tion of the embryoblast. hCG-induced P4 synthesis
therefore has, in addition to its role in uterine deciduali-
zation for the implantation and maintenance of preg-
nancy, an obligatory role before the formation of neural
precursor cells (blastulation), as well as an inductive role
in the directed differentiation and specification of the
first neuronal cell types (organogenesis; Figure 4) and
the formation of the neural tube. If future in vivo stu-
dies should confirm these in vitro results, this paracrine/
juxtacrine signaling by extraembryonic tissues would be
the commencement of trophic support by placental tis-
sues in the growth and development of the human
embryo.
Conclusions
This work demonstrates that hCG signaling via the
LHCGR induces hESC proliferation. Differentiation of
hESCs into neural precursor cells was mediated by the
upregulation of steroidogenesis by hCG signaling
through the LHCGR. Suppression of progesterone (P4)
signaling inhibited EB and neuroectodermal rosette for-
mation, suggesting an obligatory role for this steroido-
genic pathway during hESC differentiation. Together
our results suggest that pregnancy-associated hCG and
P4 could be physiologic signals that promote prolifera-
tion and differentiation during blastulation and
neurulation.
Additional material
Additional file 1: Additional data. LHCGR mRNA expression in hESCs
(Supplemental figure S1); LH and hCG regulation of Oct-3/4 expression in
hESC (Supplemental figure S2); progesterone regulation of nestin
expression in EBs and rosettes (Supplemental figure S3).
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